Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
06 07 2020
Historique:
received: 18 05 2020
accepted: 23 06 2020
entrez: 8 7 2020
pubmed: 8 7 2020
medline: 16 7 2020
Statut: epublish

Résumé

To determine the risk of SARS-CoV-2 transmission by aerosols, to provide evidence on the rational use of masks, and to discuss additional measures important for the protection of healthcare workers from COVID-19. Literature review and expert opinion. SARS-CoV-2, the pathogen causing COVID-19, is considered to be transmitted via droplets rather than aerosols, but droplets with strong directional airflow support may spread further than 2 m. High rates of COVID-19 infections in healthcare-workers (HCWs) have been reported from several countries. Respirators such as filtering face piece (FFP) 2 masks were designed to protect HCWs, while surgical masks were originally intended to protect patients (e.g., during surgery). Nevertheless, high quality standard surgical masks (type II/IIR according to European Norm EN 14683) appear to be as effective as FFP2 masks in preventing droplet-associated viral infections of HCWs as reported from influenza or SARS. So far, no head-to-head trials with these masks have been published for COVID-19. Neither mask type completely prevents transmission, which may be due to inappropriate handling and alternative transmission pathways. Therefore, compliance with a bundle of infection control measures including thorough hand hygiene is key. During high-risk procedures, both droplets and aerosols may be produced, reason why respirators are indicated for these interventions.

Identifiants

pubmed: 32631450
doi: 10.1186/s13756-020-00763-0
pii: 10.1186/s13756-020-00763-0
pmc: PMC7336106
doi:

Substances chimiques

Aerosols 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Subventions

Organisme : Bundesamt für Gesundheit
ID : NA
Pays : International

Investigateurs

Carlo Balmelli (C)
Marie-Christine Eisenring (MC)
Stephan Harbarth (S)
Jonas Marschall (J)
Didier Pittet (D)
Hugo Sax (H)
Matthias Schlegel (M)
Alexander Schweiger (A)
Laurence Senn (L)
Nicolas Troillet (N)
Andreas F Widmer (AF)
Giorgio Zanetti (G)

Références

PLoS One. 2012;7(1):e29744
pubmed: 22295066
Influenza Other Respir Viruses. 2011 May;5(3):170-9
pubmed: 21477136
JAMA. 2020 Mar 4;:
pubmed: 32129805
Lancet Infect Dis. 2020 Apr 27;:
pubmed: 32353347
JAMA. 2019 Sep 3;322(9):824-833
pubmed: 31479137
J Occup Environ Med. 2015 May;57(5):501-8
pubmed: 25816216
JAMA. 2020 Mar 26;:
pubmed: 32215590
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Infect Control Hosp Epidemiol. 2006 May;27(5):473-8
pubmed: 16671028
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Ann Intern Med. 2009 Oct 6;151(7):437-46
pubmed: 19652172
Am J Respir Crit Care Med. 2013 May 1;187(9):960-6
pubmed: 23413265
J Hosp Infect. 2020 Jun;105(2):119-127
pubmed: 32259546
CMAJ. 2016 May 17;188(8):567-574
pubmed: 26952529
Emerg Infect Dis. 2020 Jun;26(6):1059-1066
pubmed: 32187007
PLoS One. 2020 Jan 27;15(1):e0227699
pubmed: 31986165
Clin Infect Dis. 2017 Oct 15;65(8):1335-1341
pubmed: 29017249
Clin Infect Dis. 2013 Feb;56(4):617
pubmed: 23155148
N Engl J Med. 2003 Mar 27;348(13):1256-66
pubmed: 12660390
Clin Infect Dis. 2017 Nov 13;65(11):1934-1942
pubmed: 29140516
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
Ann Intern Med. 2020 Jun 2;172(11):766-767
pubmed: 32176257
Influenza Other Respir Viruses. 2020 Jul;14(4):365-373
pubmed: 32246890
Nature. 2020 Jun;582(7813):557-560
pubmed: 32340022
BMC Infect Dis. 2019 Jan 31;19(1):101
pubmed: 30704406
Emerg Infect Dis. 2005 Jul;11(7):1003-8
pubmed: 16022771
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
Rev Infect Dis. 1980 May-Jun;2(3):384-92
pubmed: 6997967
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
PLoS Pathog. 2013 Mar;9(3):e1003205
pubmed: 23505369
J Hosp Infect. 2015 Apr;89(4):225-8
pubmed: 25578684
JAMA. 2020 Feb 24;:
pubmed: 32091533
BMC Med. 2015 Sep 03;13:210
pubmed: 26336062
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
JAMA. 2009 Nov 4;302(17):1865-71
pubmed: 19797474
BMC Pulm Med. 2019 Oct 30;19(1):190
pubmed: 31666061
PLoS One. 2013;8(2):e56278
pubmed: 23418548
Emerg Infect Dis. 2020 Jul;26(7):1628-1631
pubmed: 32240078
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1081-1086
pubmed: 29348203
J Infect Dis. 2020 Apr 16;:
pubmed: 32301491
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Lancet. 2020 May 2;395(10234):e77-e78
pubmed: 32333843
N Engl J Med. 2003 Dec 18;349(25):2416-22
pubmed: 14681507
Nat Commun. 2020 May 29;11(1):2800
pubmed: 32472043
PLoS One. 2012;7(4):e35797
pubmed: 22563403
J Virol Methods. 2018 Oct;260:98-106
pubmed: 30029810
Clin Infect Dis. 2016 Mar 15;62(6):755-60
pubmed: 26679623

Auteurs

Rami Sommerstein (R)

Department of Infectious, Diseases and Hospital Hygiene, Freiburgstrasse, 3010, Bern, Switzerland. rami.sommerstein@insel.ch.
Swissnoso, the National Center for Infection Control, Bern, Switzerland. rami.sommerstein@insel.ch.

Christoph Andreas Fux (CA)

Department of Infectious Diseases and Hospital Hygiene, Aarau Cantonal Hospital, Aarau, Switzerland.

Danielle Vuichard-Gysin (D)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, Thurgau Cantonal Hospital, Thurgau, Switzerland.

Mohamed Abbas (M)

Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Jonas Marschall (J)

Department of Infectious, Diseases and Hospital Hygiene, Freiburgstrasse, 3010, Bern, Switzerland.
Swissnoso, the National Center for Infection Control, Bern, Switzerland.

Carlo Balmelli (C)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Infection Control Programme, EOC Hospitals, Ticino, Switzerland.

Nicolas Troillet (N)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland.

Stephan Harbarth (S)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Infection Control Programme and Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Matthias Schlegel (M)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Andreas Widmer (A)

Swissnoso, the National Center for Infection Control, Bern, Switzerland.
Department of Infectious Diseases, University Hospital Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH